GW1929

196808-24-9

C30H29N3O4

DMSO : >= 35 mg/mL (70.63 mM)

Cell Cycle/DNA Damage

GW1929 is a potent PPAR-gamma agonist, with a pK_i of 8.84 for human PPAR-gamma, and pEC₅₀s of 8.56 and 8.27 for human PPAR-gamma and murine PPAR-gamma, respectively. IC50 & Target: pKi: 8.84 (Human PPAR-gamma), < 5.5 (Human PPAR-alpha), < 6.5 (Human PPAR-delta)^[1]
pEC50: 8.56 (Human PPAR-gamma), 8.27 (Murine PPAR-gamma)^[1] In Vitro: GW1929 is a potent PPAR-gamma activator, with pK_is of 8.84, < 5.5, and < 6.5 for human PPAR-gamma, PPAR-alpha, and PPAR-delta, and pEC₅₀s of 8.56 and 8.27 for human PPAR-gamma and murine PPAR-gamma, respectively^[1]. GW1929 (10 uM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures^[2]. In Vivo: GW1929 (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days, and possesses antilipolytic efficacy. GW1929 (1, 5 mg/kg, p.o.) increases glucose-stimulated insuline secretion of beta-cell in ZDF rats^[1].